Overview

The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy

Status:
Unknown status

Trial end date:
2006-05-01

Target enrollment:
0

Participant gender:
All

Summary

FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Hamamatsu University

Collaborator:

Oita University

Treatments:

Amoxicillin
Clarithromycin
Dexlansoprazole
Lansoprazole

Criteria

Inclusion Criteria:

H. pylori-positive patients who have never undergo the H. pylori eradication therapy -

Exclusion Criteria:

Patients not infected with H. pylori, Patients who are allergic to amoxicillin,
clarithromycin, lansoprazole, 13C-urea, or milk casein

-